{"pmid":32361588,"pmcid":"PMC7195103","title":"Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19.","text":["Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19.","Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.","Med Hypotheses","Pindiprolu, Sai Kiran S S","Pindiprolu, Sai Harshini","32361588"],"abstract":["Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19."],"journal":"Med Hypotheses","authors":["Pindiprolu, Sai Kiran S S","Pindiprolu, Sai Harshini"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361588","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.mehy.2020.109765","keywords":["covid-19","drug discovery","niclosamide","repurposing","sars-cov-2"],"e_drugs":["Niclosamide"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495525060608,"score":9.490897,"similar":[{"pmid":32125140,"pmcid":"PMC7098069","title":"Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.","text":["Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.","The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.","ACS Infect Dis","Xu, Jimin","Shi, Pei-Yong","Li, Hongmin","Zhou, Jia","32125140"],"abstract":["The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19."],"journal":"ACS Infect Dis","authors":["Xu, Jimin","Shi, Pei-Yong","Li, Hongmin","Zhou, Jia"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125140","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1021/acsinfecdis.0c00052","keywords":["ebola virus","mers-cov","sars-cov","sars-cov-2 (covid-19)","zika virus","broad antiviral agents","coronavirus","flavivirus","human adenovirus","niclosamide"],"e_drugs":["Niclosamide"],"topics":["Treatment"],"weight":1,"_version_":1666138492805054464,"score":296.4314},{"pmid":32324951,"title":"Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.","text":["Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.","The COVID-19 pandemic caused by SARS-CoV-2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID-19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell-surface receptors, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA-dependent RNA polymerase for RNA replication. There has been a lot of ground work for drug discovery and development against these targets. Also, high-throughput screening efforts have led to the identification of diverse lead structures, including natural product-derived molecules. This review highlights past and present drug discovery and medicinal-chemistry approaches against SARS-CoV, MERS-CoV and COVID-19 targets. The review hopes to stimulate further research and will be a useful guide to the development of effective therapies against COVID-19 and other pathogenic coronaviruses.","ChemMedChem","Ghosh, Arun K","Brindisi, Margherita","Shahabi, Dana","Chapman, Mackenzie E","Mesecar, Andrew D","32324951"],"abstract":["The COVID-19 pandemic caused by SARS-CoV-2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID-19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell-surface receptors, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA-dependent RNA polymerase for RNA replication. There has been a lot of ground work for drug discovery and development against these targets. Also, high-throughput screening efforts have led to the identification of diverse lead structures, including natural product-derived molecules. This review highlights past and present drug discovery and medicinal-chemistry approaches against SARS-CoV, MERS-CoV and COVID-19 targets. The review hopes to stimulate further research and will be a useful guide to the development of effective therapies against COVID-19 and other pathogenic coronaviruses."],"journal":"ChemMedChem","authors":["Ghosh, Arun K","Brindisi, Margherita","Shahabi, Dana","Chapman, Mackenzie E","Mesecar, Andrew D"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324951","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cmdc.202000223","keywords":["covid-19","sars-cov","coronavirus","drug discovery","protease inhibitors"],"topics":["Treatment"],"weight":1,"_version_":1666138493793861635,"score":196.89903},{"pmid":32317408,"title":"Perspectives for repurposing drugs for the coronavirus disease 2019.","text":["Perspectives for repurposing drugs for the coronavirus disease 2019.","The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved marketed drugs against coronaviruses, the treatment and management of this novel CoV disease (COVID-19) worldwide is a challenge. Drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery. Direct virus-targeted antiviral agents target specific nucleic acid or proteins of the virus while host-based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection. Both the approaches necessarily interfere with viral pathogenesis. Here we summarize the present status of both virus-based and host-based drug repurposing perspectives for coronaviruses in general and the SARS-CoV-2 in particular.","Indian J Med Res","Cherian, Sarah S","Agrawal, Megha","Basu, Atanu","Abraham, Priya","Gangakhedkar, Raman R","Bhargava, Balram","32317408"],"abstract":["The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved marketed drugs against coronaviruses, the treatment and management of this novel CoV disease (COVID-19) worldwide is a challenge. Drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery. Direct virus-targeted antiviral agents target specific nucleic acid or proteins of the virus while host-based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection. Both the approaches necessarily interfere with viral pathogenesis. Here we summarize the present status of both virus-based and host-based drug repurposing perspectives for coronaviruses in general and the SARS-CoV-2 in particular."],"journal":"Indian J Med Res","authors":["Cherian, Sarah S","Agrawal, Megha","Basu, Atanu","Abraham, Priya","Gangakhedkar, Raman R","Bhargava, Balram"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317408","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijmr.IJMR_585_20","keywords":[" covid-19"," drugs"," host-based"," repurposing"," severe acute respiratory syndrome coronavirus 2"," virus-based","coronavirus"],"topics":["Treatment"],"weight":1,"_version_":1666138493633429505,"score":176.82924},{"pmid":32292909,"pmcid":"PMC7153514","title":"Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.","text":["Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.","The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.","Med Drug Discov","Liao, Jiayu","Way, George","Madahar, Vipul","32292909"],"abstract":["The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future."],"journal":"Med Drug Discov","authors":["Liao, Jiayu","Way, George","Madahar, Vipul"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292909","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100037","keywords":["covid-19","host factor","influenza virus","sars-cov-2","therapeutics","drug discovery"],"e_drugs":["remdesivir","Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138494323392512,"score":166.6431},{"pmid":32442720,"title":"A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).","text":["A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).","The epidemic of pneumonia (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has been listed as a public health emergency of international concern by the World Health Organization (WHO), and its harm degree is defined as a global \"pandemic\". At present, the efforts of various countries focus on the rapid diagnosis and isolation of patients, as well as to find a treatment that can combat the most serious impact of the disease. The number of reported COVID-19 virus infections is still increasing. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses, but there is an urgent need for in-depth research on emerging human infectious coronaviruses. Clarification transmission routes and pathogenic mechanisms, and identification of potential drug treatment targets will promote the development of effective prevention and treatment measures. In the absence of confirmed effective treatments, due to public health emergencies, it is essential to study the possible effects of existing approved antivirals drugs or Chinese herbal medicines for SARS-CoV-2. This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19. Meanwhile, this review also focus on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat COVID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID-19.","Pharmacol Res","Huang, Fangfang","Li, Ying","Leung, Elaine Lai-Han","Liu, Xiaohua","Liu, Kaifeng","Wang, Qu","Lan, Yongqi","Li, Xiaoling","Yu, Haibing","Cu, Liao","Luo, Hui","Luo, Lianxiang","32442720"],"abstract":["The epidemic of pneumonia (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has been listed as a public health emergency of international concern by the World Health Organization (WHO), and its harm degree is defined as a global \"pandemic\". At present, the efforts of various countries focus on the rapid diagnosis and isolation of patients, as well as to find a treatment that can combat the most serious impact of the disease. The number of reported COVID-19 virus infections is still increasing. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses, but there is an urgent need for in-depth research on emerging human infectious coronaviruses. Clarification transmission routes and pathogenic mechanisms, and identification of potential drug treatment targets will promote the development of effective prevention and treatment measures. In the absence of confirmed effective treatments, due to public health emergencies, it is essential to study the possible effects of existing approved antivirals drugs or Chinese herbal medicines for SARS-CoV-2. This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19. Meanwhile, this review also focus on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat COVID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID-19."],"journal":"Pharmacol Res","authors":["Huang, Fangfang","Li, Ying","Leung, Elaine Lai-Han","Liu, Xiaohua","Liu, Kaifeng","Wang, Qu","Lan, Yongqi","Li, Xiaoling","Yu, Haibing","Cu, Liao","Luo, Hui","Luo, Lianxiang"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442720","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phrs.2020.104929","keywords":["covid-19","chinese herbal medicines","pneumonia","sars-cov-2","therapeutic agents","treatment"],"locations":["Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667535119519318016,"score":164.98238}]}